Evaluating treatment effectiveness in small for gestational age children by optimizing growth hormone dose
Journal Title: Міжнародний ендокринологічний журнал - Year 2019, Vol 15, Issue 5
Abstract
Background. According to world statistics, about 5–10 % of newborns are small for gestational age (SGA). They can have inadequate rates of postnatal growth during first two years of life. This growth deficiency is observed throughout childhood and adolescence, which ultimately leads to short stature in adulthood. The purpose was to analyze the efficacy of different doses of recombinant growth hormone (rGH) therapy in order to correct growth in pre-pubertal children born small for gestational age. Materials and methods. Fifty children born small for gestational age (16 girls and 34 boys with mean age of 6.82 ± 0.36 years) with growth failure were examined. According to the results of clonidine and insulin tests, SGA patients were divided into two groups: group A — children without grown hormone deficiency (n = 34; 68 %), group B — patients with growth hormone deficiency (n = 16; 32 %). The control group included 34 persons (13 girls and 21 boys with mean age of 6.58 ± 0.38 years) with growth hormone deficiency. All patients received rGH treatment starting with a dose of 0.03 mg/kg/day according to the pituitary hormone deficiency protocol, and in case of slow growth rate, the dose was gradually increased to 0.05 mg/kg/day in group B patients. Results. A significant slowdown in growth acceleration in the first 6 months of rGH treatment at dose of 0.033 mg/kg/day was found in SGA patients without grown hormone deficiency (p < 0.05). The rGH treatment at a dose of 0.05 mg/kg/day for the next 6 months showed a statistically significant increase in growth standard deviation score (SDS) of SGA patients without growth hormone deficiency (–2.00 ± 0.14 SDS vs. –2.58 ± 0.15 SDS in the first 6 months with rGH dose of 0.033 mg/kg/day) (p < 0.05). Conclusions. The optimal dose of rGH treatment in small for gestational age children with growth hormone deficiency is 0.033 mg/kg/day, and in SGA patients without growth hormone deficiency — 0.05 mg/kg/day.
Authors and Affiliations
O. V. Bolshova, N. M. Muz
Keywords
Related Articles
- EP ID EP660839
- DOI 10.22141/2224-0721.15.5.2019.180041
- Views 56
- Downloads 0
Vitamin D status, calcium, magnesium and parathyroid hormone levels in patients with diabetes mellitus
Background. The purpose was to investigate the levels of 25(OH)D, parathyroid hormone, ionized calcium and magnesium in patients with type 1 and type 2 diabetes mellitus (DM) by comparison to the group of healthy person...
Features of left ventricular remodeling in hypothyroidism and ischemic heart disease on the background of chronic systemic inflammation
Background. Thyroid dysfunction in modern medical science is regarded as one of the risk factors for cardiovascular diseases, unfortunately, unwittingly underestimated. It is known that even insignificant violations of t...
Combined oral contraceptives: the optimal range of examination. Part 2
Combined oral contraceptives are effective drugs for contraception and treatment of reproductive disorders in polycystic ovarian syndrome. The article considers the main laboratory algorithms for excluding the most commo...
Immune histochemical study of apoptosis marker expression and proliferation in tissues at follicular neoplasia of the thyroid gland
Background. The purpose was to determine the expression of immune histochemical markers of apoptosis, р53 and bcl-2, and proliferation marker Ki-67 in follicular thyroid neoplasia. Materials and methods. Numerous immune...
New Methods of Treatment for Trophic Lesions of the Lower Extremities in Patients with Diabetes Mellitus
Introduction. Complications in the form of trophic ulcers of the lower extremities are one of the serious consequences of diabetes mellitus (DM), as they often lead to severe health and social problems, up to high amputa...